Patel NK - Search Results

1

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.

Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. Robbie GJ, et al. Among authors: patel nk. Antimicrob Agents Chemother. 2013 Dec;57(12):6147-53. doi: 10.1128/AAC.01285-13. Epub 2013 Sep 30. Antimicrob Agents Chemother. 2013. PMID: 24080653 Free PMC article. Clinical Trial.

2

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.

Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA. Zhu Q, et al. Among authors: patel nk. J Infect Dis. 2011 Mar 1;203(5):674-82. doi: 10.1093/infdis/jiq100. Epub 2011 Jan 5. J Infect Dis. 2011. PMID: 21208913 Free PMC article. Clinical Trial.

3

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Dall'Acqua WF, et al. Among authors: patel nk. J Immunol. 2002 Nov 1;169(9):5171-80. doi: 10.4049/jimmunol.169.9.5171. J Immunol. 2002. PMID: 12391234

4

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.

Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, Wrapp D, Patel NK, Cook KE, Richter BWM, Ryan PC, Yuan AQ, Suzich JA. Zhu Q, et al. Among authors: patel nk. Sci Transl Med. 2017 May 3;9(388):eaaj1928. doi: 10.1126/scitranslmed.aaj1928. Sci Transl Med. 2017. PMID: 28469033

5

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. Wu H, et al. Among authors: patel nk. J Mol Biol. 2007 May 4;368(3):652-65. doi: 10.1016/j.jmb.2007.02.024. Epub 2007 Feb 20. J Mol Biol. 2007. PMID: 17362988

6

Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays.

Deming DJ, Patel N, McCarthy MP, Mishra L, Shapiro AM, Suzich JA. Deming DJ, et al. Pediatr Infect Dis J. 2013 Oct;32(10):1144-6. doi: 10.1097/INF.0b013e31829561dd. Pediatr Infect Dis J. 2013. PMID: 23584584

7

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.

Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, Fouche L, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Kruger G, Carrim-Ganey N, Baillie V, de Oliveira T, Lombard Koen A, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G, Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen-Jose A, Foulkes S, Ahmed K, Thombrayil A, Fries L, Cloney-Clark S, Zhu M, Bennett C, Albert G, Faust E, Plested JS, Robertson A, Neal S, Cho I, Glenn GM, Dubovsky F, Madhi SA; 2019nCoV-501 Study Group. Shinde V, et al. N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5. N Engl J Med. 2021. PMID: 33951374 Free PMC article. Clinical Trial.

8

Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab.

Zhu Q, Patel NK, McAuliffe JM, Zhu W, Wachter L, McCarthy MP, Suzich JA. Zhu Q, et al. Among authors: patel nk. J Infect Dis. 2012 Feb 15;205(4):635-8. doi: 10.1093/infdis/jir790. Epub 2011 Dec 19. J Infect Dis. 2012. PMID: 22184728

9

Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein.

Xie Q, Wang Z, Ni F, Chen X, Ma J, Patel N, Lu H, Liu Y, Tian JH, Flyer D, Massare MJ, Ellingsworth L, Glenn G, Smith G, Wang Q. Xie Q, et al. PLoS One. 2019 Feb 7;14(2):e0210749. doi: 10.1371/journal.pone.0210749. eCollection 2019. PLoS One. 2019. PMID: 30730999 Free PMC article.

10

Safety and efficacy of direct oral anticoagulants in comparison to warfarin in obese patients with atrial fibrillation: A systematic review and meta-analysis.

Adelkhanova A, Oli PR, Shrestha DB, Shtembari J, Jha V, Shantha G, Bodziock GM, Biswas M, Zaman MO, Patel NK. Adelkhanova A, et al. Among authors: patel nk. Health Sci Rep. 2024 Apr 21;7(4):e2044. doi: 10.1002/hsr2.2044. eCollection 2024 Apr. Health Sci Rep. 2024. PMID: 38650729 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

328 results

Search Page